Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment

被引:142
作者
Casper, C
Nichols, WG
Huang, ML
Corey, L
Wald, A
机构
[1] Univ Washington, Virol Res Clin, Dept Med, Sch Med, Seattle, WA 98122 USA
[2] Fred Hutchinson Canc Res Ctr, Program Infect Dis, Seattle, WA 98104 USA
[3] Univ Washington, Sch Med, Dept Lab Med, Seattle, WA 98195 USA
[4] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
关键词
D O I
10.1182/blood-2003-05-1721
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multicentric Castleman disease (MCD) is a lymphoproliferative disorder associated with human herpesvirus 8 (HHV-8) infection among persons with human immunodeficiency virus (HIV) infection. Treatment often includes chemotherapy, and progression to non-Hodgkin lymphoma frequently occurs. MCD is characterized in part by active HHV-8 replication, and many of the symptoms of MCD may be attributable to viral gene products. We describe the effect of ganciclovir on the clinical and virologic course of MCD in a series of 3 case reports. Two patients experienced a reduction in the frequency of episodic flares of MCD and detectable HHV-8 DNA with intravenous or oral ganciclovir, whereas the third patient recovered from an acute episode of renal and respiratory failure with intravenous ganciclovir therapy. These data provide in vivo evidence for the utility of antiviral agents against HHV-8 in the management of MCD. (C) 2004 by The American Society of Hematology.
引用
收藏
页码:1632 / 1634
页数:3
相关论文
共 32 条
[1]   Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: The impact of highly active antiretroviral therapy [J].
Aaron, L ;
Lidove, O ;
Yousry, C ;
Roudiere, L ;
Dupont, B ;
Viard, JP .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (07) :880-882
[2]  
Albrecht H, 1997, ARCH PATHOL LAB MED, V121, P853
[3]   Interferon-α as first-line therapy for treatment of multicentric Castleman's disease [J].
Andrès, E ;
Maloisel, F .
ANNALS OF ONCOLOGY, 2000, 11 (12) :1613-1614
[4]   Treatment of EBV driven lymphoproliferation with erythrophagocytosis: 12 year follow up [J].
Bethune, CA ;
Gompels, MM ;
Taylor, C ;
Angus, B ;
Spickett, GP .
JOURNAL OF CLINICAL PATHOLOGY, 2001, 54 (04) :328-331
[5]   Quantification of human herpesvirus 8 by real-time PCR in blood fractions of AIDS patients with Kaposi's sarcoma and multicentric Castleman's disease [J].
Boivin, G ;
Côté, S ;
Cloutier, N ;
Abed, Y ;
Maguigad, M ;
Routy, JP .
JOURNAL OF MEDICAL VIROLOGY, 2002, 68 (03) :399-403
[6]   Multicentric Castleman's disease in 2 patients with HIV infection, unresponsive to antiviral therapy [J].
Bottieau, E ;
Colebunders, R ;
Schroyens, W ;
Van Droogenbroeck, J ;
De Droogh, E ;
Depraetere, K ;
De Raeve, H ;
Van Marck, E .
ACTA CLINICA BELGICA, 2000, 55 (02) :97-101
[7]  
Chronowski M, 2001, CANCER, V92, P670
[8]   Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy [J].
Corbellino, M ;
Bestetti, G ;
Scalamogna, C ;
Calattini, S ;
Galazzi, M ;
Meroni, L ;
Manganaro, D ;
Fasan, M ;
Moroni, M ;
Galli, M ;
Parravicini, C .
BLOOD, 2001, 98 (12) :3473-3475
[9]   CAN ANTIVIRAL AGENTS DECREASE THE OCCURRENCE OF KAPOSIS-SARCOMA [J].
COSTAGLIOLA, D ;
MARYKRAUSE, M .
LANCET, 1995, 346 (8974) :578-578
[10]   Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman's disease are associated with a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells [J].
Grandadam, M ;
Dupin, N ;
Calvez, V ;
Gorin, I ;
Blum, L ;
Kernbaum, S ;
Sicard, D ;
Buisson, Y ;
Agut, H ;
Escande, JP ;
Huraux, JM .
JOURNAL OF INFECTIOUS DISEASES, 1997, 175 (05) :1198-1201